Sodium DNA Lipid Nanoparticle Drug Delivery Patent
Summary
USPTO published patent application US20260090968A1 for a lipid nanoparticle composition containing sodium DNA as an active ingredient, with applications in pharmaceutical drug delivery systems. The composition includes sodium dilauramidoglutamide lysine as an amphiphilic surfactant, distearoylphosphatidylcholine as an auxiliary surfactant, cholesterol as a stabilizer, and auxiliary stabilizers including PEG-120 stearate, polyglyceryl-4 caprate, and PEG-PCL copolymer. Filing date is October 10, 2023.
What changed
USPTO published a new patent application for a lipid nanoparticle composition containing sodium DNA with specific excipients including amphiphilic and auxiliary surfactants, stabilizers, and PEG-based compounds. The composition has potential applications in pharmaceutical drug delivery. Inventors listed are Hong Geun Ji, Young Ah Park, and Yu Jin Kang.
This is a patent publication notice—regulated entities have no compliance obligations. Pharmaceutical companies and drug delivery technology developers should conduct freedom-to-operate analyses to assess whether this composition may encumber their R&D activities or product development pipelines.
What to do next
- Conduct freedom-to-operate analysis for any lipid nanoparticle-based drug delivery programs
- Review patent claims for potential licensing or collaboration opportunities
- Assess impact on existing R&D pipelines if working with sodium DNA or lipid nanoparticle compositions
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
LIPID NANOPARTICLE COMPOSITION COMPRISING SODIUM DNA
Application US20260090968A1 Kind: A1 Apr 02, 2026
Inventors
Hong Geun JI, Young Ah PARK, Yu Jin KANG
Abstract
The present invention relates to a lipid nanoparticle composition comprising sodium DNA, and more specifically relates to a lipid nanoparticle composition comprising: sodium DNA as an active ingredient; sodium dilauramidoglutamide lysine as an amphiphilic surfactant; distearoylphosphatidylcholine as an auxiliary surfactant; cholesterol as a stabilizer; an auxiliary stabilizer selected from PEG-120 stearate, polyglyceryl-4 caprate, a poly(ethylene glycol)-poly(ε-caprolactone) copolymer (PEG-PCL copolymer), and mixtures thereof; and a solvent.
CPC Classifications
A61K 8/606 A61K 8/0245 A61K 8/442 A61K 8/553 A61K 8/63 A61K 8/86 A61K 8/90 A61Q 19/00 A61K 2800/413
Filing Date
2023-10-10
Application No.
19114983
Named provisions
Related changes
Get daily alerts for ChangeBridge: Patent Apps - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: Patent Apps - Pharma (A61K) publishes new changes.